- Home
- »
- Pharmaceuticals
- »
-
Cystic Fibrosis Therapeutics Market Size, Share Report 2030GVR Report cover
Cystic Fibrosis Therapeutics Market (2025 - 2030) Size, Share & Trends Analysis Report By Drug Class (Pancreatic Enzyme Supplements), By Route of Administration (Oral), By Distribution Channel, By Region, And Segment Forecasts
Market Size, 2024
$10.3BMarket Estimate, 2026
$10.7BMarket Forecast, 2030
$22.7BCAGR, 2025–2030
14.2%Cystic Fibrosis Therapeutics Market Summary
The global cystic fibrosis therapeutics market size was estimated at USD 10.3 billion in 2024 and is projected to reach USD 22.7 billion by 2030, growing at a CAGR of 14.2% from 2025 to 2030. This growth is attributed to the increasing prevalence of cystic fibrosis and rising treatment rates.
Source: Grand View Research, IR Documents, Primary Interviews, Paid DatabasesTo learn more about this report,
Download Free Sample Report Key Market Trends & Insights
- The North America cystic fibrosis therapeutics market dominated the global market and accounted for the largest revenue share of 59.8% in 2024.
- The cystic fibrosis therapeutics market in the U.S. dominated North America in 2024.
- Based on drug, CFTR modulators dominated the market and accounted for the largest revenue share of 44.0% in 2024.
- In terms of route of administration, The growth of oral administration led the market and accounted for the largest revenue share of 69.0% in 2024.
- On the basis of distribution channel, Hospital pharmacies led the market and accounted for the largest revenue share, 53.5%, in 2024.
Market Size & Forecast
- 2024 Market Size: USD 10.3 billion
- 2030 Projected Market Size: USD 22.7 billion
- CAGR (2025-2030): 14.2%
- North America: Largest market in 2024
Three ways to get this report
Buy it, customize it, or ask a question.Ask an Analyst
Analyst response in 1 business day
- AccessReport author, directly
- Reply timeWithin 1 working day
- No sales callDirect answer only
- FormatEmail reply
- CostFree, no cost
Get the Full Report
What the study covers
- FormatsPDF · Excel · Dashboard
- Timeline2025–2030 annual, 2024 base
- Coverage20+ countries, 5 regions
- Companies10+ key players profiled
Customize the Report
20% free customization
- IncludeCountries, segments, points
- TailorTo your product definition
- ExtendDeeper competitor detail
- OrA fully bespoke study
- Turnaround5–10 working days
In addition, enhanced research and development funding from private and public sectors and favorable reimbursement policies support market growth. Furthermore, introducing innovative therapies, particularly CFTR modulators, and a growing number of clinical trials to expand the patient base further contribute to market expansion. Moreover, increased awareness among healthcare professionals and patients about advanced treatment options also plays a crucial role in boosting demand.
To learn more about this report, Download Free Sample Report Cystic fibrosis (CF) is a genetic disorder characterized by mutations that disrupt the normal function of proteins responsible for the secretion of fluids in the body. This malfunction produces thick mucus and sweat, affecting various organs, particularly the lungs and digestive system. The condition impairs the electrolyte transport system, causing cells to retain sodium and water, which exacerbates issues related to sweat and mucus-producing glands. As a result, individuals with CF often experience heightened susceptibility to respiratory infections, chronic coughs, hemoptysis, and lung collapses. Furthermore, gastrointestinal complications arise from difficulty absorbing essential nutrients such as proteins, fats, and vitamins, further complicating patient health and contributing to market growth for CF treatments.
In addition, the increasing prevalence of CF is a significant driver for the therapeutics market, spurring the development of new drugs to address respiratory and gastrointestinal challenges. Recent advancements include therapies that target cellular defects inherent in CF, which promise to be transformative for many patients.
Moreover, as more patients are diagnosed and seek treatment options, the demand for effective therapies continues to rise. The introduction of novel medications targeting the underlying genetic issues of CF is anticipated to stimulate market expansion further. With numerous candidates nearing completion in clinical trials, the landscape for cystic fibrosis therapeutics is evolving rapidly, setting the stage for substantial growth in this sector over the coming years.
Market Dynamics
The increasing adoption of CFTR modulator therapies remained the key driver of the cystic fibrosis therapeutics market, as these treatments address the underlying genetic cause of cystic fibrosis rather than only controlling symptoms. The growing use of advanced therapies significantly improved lung function, nutritional outcomes, and patient survival rates, which accelerated global treatment demand. Rising regulatory approvals, supportive reimbursement policies, and increasing investments in precision medicine further contributed to market expansion. Pharmaceutical companies also focused on developing next-generation modulators to expand treatment eligibility for patients with rare CFTR mutations. For instance, in April 2026, Vertex Pharmaceuticals announced that the U.S. FDA had approved label expansions for ALYFTREK and TRIKAFTA, making nearly 95% of cystic fibrosis patients in the United States eligible for CFTR modulator therapies and expanding treatment access to approximately 800 additional patients nationwide.
The high cost of cystic fibrosis therapies remained a significant restraint for the cystic fibrosis therapeutics market, limiting treatment accessibility and affordability across several regions, particularly in low- and middle-income countries. Advanced CFTR modulator therapies entail extremely high annual treatment costs, placing financial pressure on patients, healthcare systems, and payers. Limited insurance coverage, delayed reimbursement approvals, and unequal access to specialized healthcare facilities further restricted therapy adoption. In addition, the substantial costs associated with research, clinical development, and commercialization of rare disease therapies continued to elevate product pricing globally. These pricing challenges reduced treatment penetration in emerging healthcare markets despite increasing disease awareness and diagnosis rates. For instance, in September 2025, Prime Therapeutics reported that Vertex Pharmaceuticals’ Trikafta had a wholesale acquisition cost of approximately USD 370,000 annually per patient in the United States, highlighting ongoing affordability concerns and access barriers for cystic fibrosis patients worldwide.
The expansion of gene and mRNA-based therapies created a major growth opportunity for the cystic fibrosis therapeutics market, as these advanced technologies aim to provide long-term, potentially curative treatment solutions. Increasing investments in genetic medicine, rising collaborations between biotechnology and pharmaceutical companies, and growing research activities accelerated innovation in therapies targeting the underlying cause of cystic fibrosis. Supportive regulatory pathways for rare disease therapies also strengthened market opportunities. In addition, advancements in inhaled drug-delivery technologies improved the effectiveness of next-generation therapies for patients who were not eligible for existing CFTR modulators. For instance, in January 2025, Vertex Pharmaceuticals stated in its annual report that its investigational VX-522 mRNA therapy, developed in collaboration with Moderna, Inc., had the potential to benefit more than 5,000 cystic fibrosis patients across the U.S., Canada, Europe, and Australia who could not benefit from currently approved CFTR modulators.
Drug Insights
CFTR modulators dominated the market and accounted for the largest revenue share of 44.0% in 2024 attributed to their ability to target the underlying genetic defects of the disease. In addition, introducing drugs such as Orkambi has significantly impacted revenue due to their effectiveness in correcting defective protein functions caused by CF mutations. Furthermore, a robust pipeline of new CFTR modulators, including combination therapies, is anticipated to enhance market growth further. Moreover, increased research and development funding and supportive reimbursement policies contribute to this trend, as they facilitate the introduction of innovative therapies to improve patient outcomes.
Pancreatic enzyme supplements are expected to grow at a CAGR of 14.8% over the forecast period, owing to their critical role in managing gastrointestinal complications associated with CF. Patients often face difficulties in nutrient absorption, making these supplements essential for improving digestive health and overall quality of life. In addition, the rising prevalence of cystic fibrosis and an increasing number of patients seeking treatment are key factors driving demand for these supplements. Furthermore, advancements in formulation and delivery methods are enhancing their effectiveness, thereby propelling market growth.
Route of Administration Insights
The growth of oral administration led the market and accounted for the largest revenue share of 69.0% in 2024 attributed to oral medications' convenience and ease of use. Patients prefer oral formulations due to their non-invasive nature, which enhances adherence to treatment regimens. In addition, the increasing availability of effective oral therapies, such as CFTR modulators, has expanded patient treatment options. These medications improve lung function and address nutritional deficiencies, making them crucial for comprehensive care. Furthermore, the rising prevalence of cystic fibrosis further fuels the demand for accessible oral treatments, contributing to market growth.
Inhaled therapies are expected to grow at a CAGR of 14.8% over the forecast period, owing to their targeted delivery and rapid onset of action. Inhaled medications, such as mannitol and inhaled corticosteroids, directly address lung function by improving mucus clearance and reducing inflammation. In addition, inhaled therapies are particularly effective in managing respiratory symptoms and preventing infections, which are common complications in CF patients. Furthermore, developing advanced inhalation devices has also improved drug delivery efficiency and patient compliance, thereby driving market expansion.
Distribution Channel Insights
Hospital pharmacies led the market and accounted for the largest revenue share, 53.5%, in 2024 driven by their critical role in providing timely access to specialized medications. In addition, this setting ensures that patients receive immediate care during inpatient stays or outpatient appointments, enhancing treatment adherence and outcomes. Furthermore, the increasing prevalence of cystic fibrosis necessitates more hospital visits, further driving the demand for hospital pharmacy services.
To learn more about this report, Download Free Sample Report Online pharmacies are expected to grow at the fastest CAGR over the forecast period, owing to their convenience and accessibility. Patients can order medications from the comfort of their homes, allowing for quick access to a wide range of therapies and related products. In addition, the rise of e-commerce and digital health platforms has simplified medication management for chronic illnesses such as cystic fibrosis, making it easier for patients and caregivers to obtain necessary treatments. Furthermore, competitive pricing and the ability to compare options online enhance consumer preference for online pharmacies, contributing to their expanding role in distributing cystic fibrosis therapeutics.
Regional Insights
The North America cystic fibrosis therapeutics market dominated the global market and accounted for the largest revenue share of 59.8% in 2024 attributed to a combination of high prevalence rates and advanced healthcare infrastructure. Substantial investments in research and development, along with supportive government policies and reimbursement frameworks, enhance access to cutting-edge treatments. Furthermore, the presence of major pharmaceutical companies and ongoing clinical trials further contribute to a dynamic market environment, ensuring continuous advancements in CF care.
To learn more about this report, Download Free Sample Report U.S. Cystic Fibrosis Therapeutics Market Trends
The cystic fibrosis therapeutics market in the U.S. dominated North America in 2024. A robust healthcare system and a high level of awareness regarding the disease drive this growth. In addition, the increasing incidence of cystic fibrosis and improved diagnostic techniques have led to earlier detection and treatment initiation. Furthermore, the growing patient population seeking effective treatments drives demand for innovative drug formulations, enhancing market growth prospects.
Latin America Cystic Fibrosis Therapeutics Market Trends
Latin America cystic fibrosis therapeutics market is expected to grow at a CAGR of 17.8% from 2025 to 2030, owing to rising awareness of the disease and improved healthcare access. In addition, countries in this region are increasingly adopting advanced treatment options, supported by initiatives from non-profit organizations to educate patients and healthcare providers. Furthermore, the growing prevalence of cystic fibrosis is prompting governments to allocate more resources toward research and development, ultimately leading to enhanced therapeutic options for patients in Latin America.
Asia Pacific Cystic Fibrosis Therapeutics Market Trends
The cystic fibrosis therapeutics market in Asia Pacific is expected to grow significantly over the forecast period attributed to increasing healthcare investments and rising patient awareness. In addition, the region's expanding healthcare infrastructure facilitates better access to advanced treatments for cystic fibrosis. Furthermore, a growing number of clinical trials and research initiatives are focusing on developing effective therapies tailored to the needs of patients in this diverse region. As awareness rises, more patients seek treatment options, further propelling market growth.
China cystic fibrosis therapeutics market is growing substantially, owing to a significant increase in disease diagnosis and subsequent treatment demand. In addition, the Chinese government prioritizes rare diseases such as cystic fibrosis within its healthcare agenda, leading to improved access to innovative therapies. Furthermore, collaborations between local pharmaceutical companies and international firms foster the development of targeted treatments tailored to the Chinese population. This focus on enhancing healthcare delivery systems contributes positively to market growth.
Europe Cystic Fibrosis Therapeutics Market Trends
The cystic fibrosis therapeutics market in Europe accounted for a significant revenue share in 2024 attributed to a strong regulatory framework that supports drug approval processes and patient access to novel therapies. In addition, the increasing incidence of cystic fibrosis across various European countries drives demand for effective treatment options. Furthermore, heightened collaboration among healthcare providers, researchers, and pharmaceutical companies fosters innovation in CF therapies.
Key Cystic Fibrosis Therapeutics Company Insights
Some of the key companies in the cystic fibrosis therapeutics market include AbbVie Inc. F. Hoffmann-La Roche Ltd, Gilead, Novartis AG, and others. These Companies focus on innovative research and development, alongside strategic mergers and collaborations, to enhance their competitive advantage in the cystic fibrosis therapeutics market. Furthermore, launching new products and forming partnerships aims to improve treatment outcomes and expand their market presence effectively.
-
AbbVie Inc. develops and manufactures advanced therapies for various diseases, including cystic fibrosis (CF). Although AbbVie has faced challenges in developing effective CF treatments, it has engaged in strategic partnerships to enhance its pipeline. The company focuses on innovative drug formulations, particularly CFTR modulators, and has recently licensed several clinical-stage compounds to Sionna Therapeutics, aiming to leverage its research capabilities and strengthen its position in the cystic fibrosis therapeutics market.
-
F. Hoffmann-La Roche Ltd. manufactures various medications for various therapeutic areas, including cystic fibrosis. The company is committed to advancing treatments that address the underlying causes of CF through innovative drug development. Roche's extensive research and development efforts focus on creating targeted therapies and improving patient outcomes, positioning it as a key player in the cystic fibrosis therapeutics segment.
Key Cystic Fibrosis Therapeutics Companies:
The following are the leading companies in the cystic fibrosis therapeutics market. These companies collectively hold the largest market share and dictate industry trends.
- AbbVie Inc.
- F. Hoffmann-La Roche Ltd
- Gilead
- Novartis AG
- Vertex Pharmaceuticals Incorporated
- AIT (Advanced Inhalation Therapies)
- Alaxia
- Teva Pharmaceutical Industries Ltd.
- Merck & Co. Inc.
- Sionna Therapeutics
- Alcresta Therapeutics, Inc.
- AstraZeneca
Competitive Benchmarking
Operating Strategies
Competitive Edge
Weaknesses
Mature Players: Vertex Pharmaceuticals Incorporated
- Mature players focus on expanding CFTR modulator portfolios, strengthening global commercialization capabilities, securing regulatory approvals, and increasing investments in advanced cystic fibrosis therapies. They also emphasize strategic collaborations, precision medicine research, and geographic expansion strategies to maintain long-term market leadership and competitive positioning globally.
- Mature players maintain a competitive advantage through established commercialized therapy portfolios, advanced research infrastructure, strong financial resources, and extensive global distribution networks. Their regulatory expertise, broad clinical data, and strong patient access programs support higher treatment adoption rates and help sustain dominant market positions across international markets.
- Mature players face challenges including high research and development costs, strict regulatory compliance requirements, pricing pressure on premium therapies, and increasing competition from emerging pipeline products. Dependence on blockbuster cystic fibrosis therapies may also create long-term revenue concentration risks and limit future operational flexibility in changing markets.
Emerging Players: Sionna Therapeutics
- Emerging players prioritize innovation-driven strategies focused on next-generation CFTR correction technologies and novel small-molecule therapies targeting the underlying cause of cystic fibrosis. They emphasize rapid clinical development, licensing agreements, research collaborations, and targeted investments to accelerate commercialization, strengthen pipeline development, and enhance global market presence.
- Emerging players gain a competitive advantage through technological innovation, scientific agility, and specialized expertise in rare genetic disease research. Their focused approaches to CFTR protein stabilization and mutation-specific therapies support differentiated pipeline development, faster innovation cycles, greater adaptability, and long-term growth opportunities in cystic fibrosis treatment markets.
- Emerging players often face limited commercialization capabilities, lower brand recognition, funding dependency, and restricted global distribution networks. They may also experience difficulties scaling manufacturing operations, obtaining widespread regulatory approvals, and competing with established pharmaceutical companies that possess stronger financial, operational, and commercial infrastructure globally.
Recent Developments
-
In July 2024, Sionna Therapeutics announced a significant expansion of its cystic fibrosis therapeutics pipeline through a licensing agreement with AbbVie. This agreement grants Sionna exclusive worldwide rights to develop and commercialize multiple clinical-stage compounds, including two Phase 2 compounds. These compounds aim to enhance treatment efficacy by stabilizing the CFTR protein. The collaboration positions Sionna to advance innovative combination therapies, potentially transforming the landscape of cystic fibrosis treatment.
Cystic Fibrosis Therapeutics Market Report Scope
Report Attribute
Details
Market size value in 2025
USD 11.7 billion
Revenue forecast in 2030
USD 22.7 billion
Growth rate
CAGR of 14.2% from 2025 to 2030
Base year for estimation
2024
Historical data
2018 - 2023
Forecast period
2025 - 2030
Quantitative units
Revenue in USD Million and CAGR from 2025 to 2030
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Drug class, route of administration, distribution channel, region
Regional scope
North America, Europe, Asia Pacific, Latin America, MEA
Country scope
U.S., Canada, UK, Germany, France, Italy, Spain, Denmark, Sweden, Norway, Russia, India, China, South Korea, Hong Kong, Australia, Singapore, Brazil, Argentina, Kuwait, Qatar, Saudi Arabia, South Africa, UAE
Key companies profiled
AbbVie Inc.; F. Hoffmann-La Roche Ltd; Gilead; Novartis AG; Vertex Pharmaceuticals Incorporated; AIT (Advanced Inhalation Therapies); Alaxia; Teva Pharmaceutical Industries Ltd.; Merck & Co. Inc.; Sionna Therapeutics; Alcresta Therapeutics, Inc.; AstraZeneca
Customization scope
Free report customization (equivalent to 8 analyst working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
Global Cystic Fibrosis Therapeutics Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and analyzes the latest industry trends in each sub-segment from 2018 to 2030. For this study, Grand View Research has segmented the global cystic fibrosis therapeutics market report based on drug class, route of administration, distribution channel, and region:
To learn more about this report, Download Free Sample Report -
Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
-
CFTR Modulators
-
Pancreatic Enzyme Supplements
-
Mucolytics
-
Bronchodilators
-
-
Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
-
Oral
-
Inhaled
-
-
Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
-
-
Regional Outlook (Revenue, USD Million, 2018 - 2030)
-
North America
-
U.S.
-
Canada
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
Russia
-
-
Asia Pacific
-
India
-
China
-
South Korea
-
Hong Kong
-
Australia
-
Singapore
-
Japan
-
New Zealand
-
Thailand
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East and Africa (MEA)
-
Kuwait
-
Qatar
-
Saudi Arabia
-
South Africa
-
UAE
-
-
Delivered Customizations
This report has been delivered with the following In-depth customizations
Client Request
Customization Delivered
Value Adds
CFTR Modulator Commercial Opportunity Assessment (U.S. & Europe)
- Conducted a targeted assessment of CFTR modulator therapy opportunities across the U.S., Germany, France, Italy, Spain, and the UK The study evaluated eligible cystic fibrosis patient populations, reimbursement frameworks, treatment adoption trends, regulatory approvals, pricing benchmarks, and physician prescribing behavior for advanced CFTR therapies.
- Helped the client identify high-growth commercialization markets, evaluate pricing and reimbursement potential, optimize launch strategies, and understand competitive positioning against established cystic fibrosis therapy manufacturers across major developed healthcare markets with strong rare disease treatment infrastructure and reimbursement support systems.
Next-Generation Gene Therapy & mRNA Pipeline Benchmarking
- Delivered a comprehensive benchmarking study on gene therapy and mRNA-based cystic fibrosis developers focusing on Vertex Pharmaceuticals, Moderna, and emerging biotechnology companies. The assessment covered Phase I-III clinical pipelines, delivery technologies, licensing agreements, manufacturing scalability, intellectual property positioning, and commercialization readiness for mutation-specific therapies.
- Enabled the client to identify strategic partnership and acquisition opportunities, evaluate white-space opportunities in rare genetic disease treatment markets, and prioritize investment decisions in next-generation cystic fibrosis therapeutic platforms with strong long-term commercialization and precision medicine growth potential across global healthcare markets.
Rare Disease Treatment Accessibility & Market Expansion Feasibility Study
- Conducted a country-level feasibility assessment for cystic fibrosis therapeutic expansion across Asia-Pacific, Latin America, and Middle East regions. The study analyzed diagnostic infrastructure, reimbursement accessibility, regulatory pathways, healthcare spending trends, patient identification rates, and distribution challenges associated with advanced cystic fibrosis treatment adoption in emerging healthcare markets.
- Supported long-term expansion planning by identifying high-potential emerging markets, reimbursement access opportunities, treatment adoption barriers, and strategic collaboration possibilities with healthcare providers and government agencies to strengthen cystic fibrosis diagnosis, patient access, and commercial sustainability in underserved regional healthcare systems.
About the Author(s)
Pharmaceuticals Research Team
Healthcare · PharmaceuticalsThis report was authored by the pharmaceuticals research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the pharmaceuticals segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs - add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
